Plain-English translation of NCT07005154 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called , which is an injectable form of a hormone therapy used to treat advanced prostate cancer. The medication works by blocking testosterone from reaching cancer cells. Researchers want to see whether this medication works as well as the standard tablet form, and whether it can be given safely with or without an additional steroid medication.
Current hormone therapy for advanced prostate cancer requires taking a daily tablet along with a steroid, which can be inconvenient and may cause side effects. This trial is exploring whether the new injectable form of the medication—given once every 12 weeks—might be easier for patients to use and work just as well.
You likely qualify if…
You likely don't qualify if…
Depending on which group you are in, you will receive either the new injectable medication every 12 weeks or the standard tablet form once daily, possibly along with a steroid medication taken one or two times daily. You will have regular visits to check how well the treatment is working and to monitor for any side effects, with blood tests and imaging scans as needed. The study will continue until your cancer progresses or you experience side effects that require stopping treatment.
AI-generated summary from trial data · Jul 11, 2026 · Not medical advice
United States
Male only
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Astellas Pharma Global Development, Inc.
Astellas Pharma Global Development, Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.